Global Plasma Fractionation Market is predicted to hit USD 27.46 billion by 2021

Posted by rohan on September 20th, 2017

The Global Plasma Fractionation Market was worth USD 19.4 billion in 2016 and is projected to be growing at a CAGR of 7.2%, to touch USD 27.46 billion by 2021. Blood fractionation is the process of fractionating whole blood or segregating it into its constituent parts. Whole blood consists of red cells, white cells, and platelets, suspended in plasma, which constitutes about 55% of blood by volume.

Browse Market data tables and in-depth TOC of the Global Plasma Fractionation Market to 2021 @http://www.marketdataforecast.com/market-reports/plasma-fractionation-market-2837/

Plasma is the liquid portion of blood. It not only consists of red cells, white cells and platelets suspended in it, but also contains thousands of distinct proteins and other substances like electrolytes, minerals, hormones, etc., which are necessary for the normal function of the human body. Plasma helps in maintaining blood pressure and body temperature regulation.

The growth of the Global Plasma Fractionation Market is mainly driven by factors such as increasing incidence of immune and bleeding disorders, growing incidence of Alpha-1 Antitrypsin deficiency and the rising use of immunoglobulins, which are basically antibodies. Further, growing aging population with related blood related ailments is set to further drive market growth. However, adverse reactions associated with the use of plasma fractionation and transfer, high costs of plasma products and unfavourable reimbursement policies are the major constraints of market growth.

Free sample of the report is available @http://www.marketdataforecast.com/market-reports/plasma-fractionation-market-2837/request-sample

The Global Plasma Fractionation Market is segmented on the basis of Product, Application, End User and Geography. Based on Product, the market is divided into Albumin, Immunoglobulin, Factor VIII, and Protease Inhibitors. Based on Application, the Plasma Fractionation Market is segmented into Neurology, Haematology, Rheumatology, Pulmonology, and Immunology. Based on the End User, it is categorized into Hospital and Clinical Laboratories.

The market has been geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. As of 2016, North America leads the market, with the U.S. accounting for a major share. North America’s lead is justified by the presence of high number of registered haemophilic patients and increasing use of immunoglobulins in neurologic disorders. Europe comes in second in terms of market share owing to the rising awareness about blood related disorders and the swift availability of treatment in terms of plasma fractionation. However, Asia-Pacific is estimated to grow at the highest CAGR during the forecast period majorly because of the presence of larger elderly population numbers leading to higher incidence of blood disorders.

The major players in the Plasma Fractionation market are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), KedrionS.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and LaboratoireFrançais du Fractionnementet des Biotechnologies (France).